News & Updates

Show Multimedia Only

Tacrolimus or cyclosporine for CLAD: The better of 2 immunosuppressants

28 Sep 2023 by

Tacrolimus given once daily significantly reduced the 3-year incidence of chronic lung allograft dysfunction (CLAD) in lung transplant patients compared with standard immunosuppressant in the open label, multicentre, ScanCLAD trial presented at ERS 2023.

Tacrolimus or cyclosporine for CLAD: The better of 2 immunosuppressants

28 Sep 2023

Atezolizumab-chemo confers durable survival benefit in ES-SCLC

27 Sep 2023 by

In the merged analysis of the IMpower133 trial and IMbrella A open-label extension study, the combination of the PD-L1 inhibitor atezolizumab and a chemotherapy regimen comprising carboplatin and etoposide (CP/ET) demonstrated potential for survival benefit of up to 5 years in patients with extensive stage-small-cell lung cancer (ES-SCLC).

Atezolizumab-chemo confers durable survival benefit in ES-SCLC

27 Sep 2023

Passive smoking: Does it influence risk of childhood atopic eczema, food allergy?

26 Sep 2023 by

A systematic review and meta-analysis from Singapore demonstrates that parental smoking is not a strong risk factor for offspring eczema, food allergy, and food sensitization development.

Passive smoking: Does it influence risk of childhood atopic eczema, food allergy?

26 Sep 2023

Dupilumab improves lung function in children with moderate-to-severe type 2 asthma

26 Sep 2023 by

Treatment with dupilumab significantly improved lung function in children with moderate-to-severe type 2 asthma compared with placebo, according to two post hoc analyses presented at ERS 2023.

Dupilumab improves lung function in children with moderate-to-severe type 2 asthma

26 Sep 2023

Is CPAP cardioprotective?

25 Sep 2023 by

Two studies presented at ERS 2023 demonstrated the potential of a continuous positive airway pressure (CPAP) machine to address cardiovascular (CV) risks in individuals with obstructive sleep apnoea (OSA).

Is CPAP cardioprotective?

25 Sep 2023

Vaping tied to chronic stress, poor QoL in young adults

23 Sep 2023 by

Use of e-cigarette (EC) shows a significant relation with a higher incidence of chronic stress and is indicative of poorer quality of life (QoL) in young adults, suggests a study presented at ERS 2023.

Vaping tied to chronic stress, poor QoL in young adults

23 Sep 2023

Fatigue in COPD influenced by multiple contributing factors

22 Sep 2023 by

Fatigue in people with chronic obstructive pulmonary disease (COPD) may be caused by factors such as shortness of breath, sleep quality, pain, and fatigue-related catastrophizing, according to the FAntasTIGUE study.

Fatigue in COPD influenced by multiple contributing factors

22 Sep 2023

Benralizumab helps maintain severe asthma control with reduced ICS doses

22 Sep 2023 by

Treatment with benralizumab allows tapering of inhaled corticosteroid (ICS) doses for patients with severe eosinophilic asthma, without compromising disease control and increasing exacerbations, as shown in the results of the phase IV SHAMAL study.

Benralizumab helps maintain severe asthma control with reduced ICS doses

22 Sep 2023

Smoking speeds up ageing process

22 Sep 2023 by

A recent Mendelian randomization (MR) study provides genetic evidence showing that smoking can accelerate ageing as a result of shortened leucocyte telomere length (LTL). However, quitting may help reduce such risk.

Smoking speeds up ageing process

22 Sep 2023

Benralizumab reduces asthma exacerbations in Asians

22 Sep 2023 by

Treatment with benralizumab significantly reduces the annual asthma exacerbation rate (AAER) among Asian patients with severe uncontrolled asthma compared with placebo, according to a subgroup analysis of the MIRACLE trial presented at ERS 2023.

Benralizumab reduces asthma exacerbations in Asians

22 Sep 2023

News & Updates

Showing Respirology articles

Showing

Specialty:

Tacrolimus or cyclosporine for CLAD: The better of 2 immunosuppressants

Tacrolimus or cyclosporine for CLAD: The better of 2 immunosuppressants

Atezolizumab-chemo confers durable survival benefit in ES-SCLC

Atezolizumab-chemo confers durable survival benefit in ES-SCLC

Passive smoking: Does it influence risk of childhood atopic eczema, food allergy?

Passive smoking: Does it influence risk of childhood atopic eczema, food allergy?

Dupilumab improves lung function in children with moderate-to-severe type 2 asthma

Dupilumab improves lung function in children with moderate-to-severe type 2 asthma

Is CPAP cardioprotective?

Is CPAP cardioprotective?

Vaping tied to chronic stress, poor QoL in young adults

Vaping tied to chronic stress, poor QoL in young adults

Fatigue in COPD influenced by multiple contributing factors

Fatigue in COPD influenced by multiple contributing factors

Benralizumab helps maintain severe asthma control with reduced ICS doses

Benralizumab helps maintain severe asthma control with reduced ICS doses

Smoking speeds up ageing process

Smoking speeds up ageing process

Benralizumab reduces asthma exacerbations in Asians

Benralizumab reduces asthma exacerbations in Asians